Preventing eye disease using nanotechnology

Eximore has developed a first-of-its-kind nanotechnology device to treat chronic eye diseases and prevent severe eyesight damage., based on a non-invasive, revolutionary device for an sustained and controlled release of eye medication over time

60% From funding target


Units left


Minimum investment


Days to go
By: Eyal Sheetrit
Public Campaign
Company Stage:
Medical Devices

Campaign Highlights

Campaign Highlights

A revolutionary nanomedical device that can prevent blindness

In treating many disease types, the global ophthalmology sector still relies on the outdated and manual use of eye drops, which are not always effective or sterile and depend on the patient's ability to comply with a strict treatment plan. Eximore offers an advanced first-of-its-kind solution that allows sustained and controlled release of eye drop meds using a flexible implant inserted into the tear duct in a quick, non-invasive procedure. The development, based on nanotechnological engineering of advanced materials, is currently intended for treating glaucoma and dry eye conditions (to be expanded later on for use in other eye conditions, such as allergies) and is aimed at the global ophthalmology market, valued at billions of dollars.

Eximore's top investors include Xenia Venture Capital, CBG Group, Rimonci Capital Innovation Authority

Since its establishment in 2013, Eximore has operated as part of the VLX incubator in Jerusalem and has received several development grants from by the Innovation Authority. Furthermore, the company has raised substantial capital for clinical trials from the Chinese investment fund Rimonci, which specializes in ophthalmology-related companies. In addition, it has obtained funding from the Consensus Business Group (CBG), led by top investor Vincent Tchenguiz.

Efficacy has been proven in clinical trials at international hospitals

After proving the safety and efficacy of its product in preclinical trials, Eximore is now in the final stages of its first clinical trial as part of a research collaboration with Latin American hospitals. The results have shown that this medical device effectively releases the required medication in glaucoma conditions, lowers intraocular pressure more efficiently and safely than eye drops, and allows long-term treatment for over three months. In dry eye conditions, trials have shown that the product significantly improves the patient's condition, treats inflammation and other symptoms more successfully, and restores the tear functions  efficiently than artificial tear drop treatments.

Patented IP in international registration stages

Eximore holds the exclusive international license to commercialize its intellectual property, based on a license obtained from ShebaTel Hashomer Medical Center. The company has registered a series of patents related to the formulation of its device. Eximore's glaucoma product patent has already been granted, while its dry eye product patent is in the international registration phase.

Immediate market entry and technological superiority over competitors

Currently, there is no direct competitor with any product approved for commercial use (or even a planned product). The company's technology comprises a unique combination of generic eye drops thet have established and well-known safety profile, used in our smart medical device. These advantages will shorten the market entry time, remove the need for medical training of doctors, and allow staff to start using this new technology smoothly. The exclusivity of the technology establishes the company as the next market leader for eye disease treatments.



The Idea

The Need

Glaucoma refers to a group of eye diseases that cause irreversible damage to the optic nerve and damage eyesight - or even total blindness. Although proper continuous treatment with eye drops can prevent this, patients usually struggle to comply with long-term treatments. Research has shown that ~40% of them stop their treatment regimen after only 6 months, which increases chances of damage to their eyesight.

Glaucoma is a chronic disease characterized by higher-than-normal intraocular pressure (above 21 mmHg) and gradual visual field loss caused by dying nerve cells (retinal ganglion cells). Since the loss of the visual field is mainly peripheral (meaning, the central visual ability is not impaired until the final stages of the disease), patients are usually unaware of their condition until a very late stage. Glaucoma has been called the “silent thief of sight," and is, in fact, one of the leading causes of irreversible blindness.

The treatment currently offered to most glaucoma patients is based on eye drops in order to lower intraocular pressure, with trabeculectomy performed only in severe cases. Eye drop treatment is required up to several times a day for the rest of a patient’s life.  95% of glaucoma patients are currently treated in this manner, receiving one or several substances; however, despite the risk of visual impairment or blindness, compliance remains only 60%.

Due to low compliance with the prescribed treatment (with most patients applying their drops regularly only when nearing their 6-month doctor's check-up appointment), this problem has been discussed in almost every ophthalmology journal. However, surgical solutions involve side effects, such as cataract progression, risk of infection, and local irritation and redness. Therefore, surgery is usually reserved for later and more severe stages. In most glaucoma cases, treatment is primarily pharmacological, with doctors and patients dealing with the resulting complications.

Other issues arising from eye drop treatment include situations in which patients often drip either too much or little to no substance, or in which tears wash away the active ingredient without being absorbed therfore have no effect. In addition, many of the drops in commercial use contain preservatives, which produce common side effects such as redness and dry eyes.

Eximore solves this significant problem by transitioning from eye drops to our smart and groundbreaking nanomedical device. In addition to providing chronic long-term care, the solution treats various conditions, thus replacing other non-effective short-term treatments. 


The Solution

Eximore's product is initially intended for ophthalmological use in glaucoma conditions; the company plans to expand into treating dry eye conditions, which are very common and are similarly treated with drops. The product is aimed at almost 50% of all patients who do not receive proper treatment or cannot comply with it, whether due to motoric problems, or memory issues, since most of these patients tend to be elderly or ill.

Eximore's nanomedical device performs a controlled, long-term, sustained release of a generic drug (latanoprost) to lower intraocular pressure in patients with glaucoma. The patented device is inserted into the lower tear duct of the eye (its natural canal) in a non-invasive procedure, similar to inserting contact lenses - so that the drug is released uniformly over 3-12 months. The device is comfortable and aesthetic:   patients do not feel it, and it is not noticeable.

The device effectively eliminates the need to manually administer eye drop medication daily and solves the problem of patient compliance over time when dealing with chronic eye diseases.

                                  Demonstrating the scale of Eximore’s implant

How does it work?

The device created by the company is a punctal plug of only millimeter long.

The plug is based on nanotechnological engineering of advanced materials that allow for large-scale drug storage and diffusion release in a measured and accurate dose per day (similar to the effect of eye drops). The plug consists of a drug adsorbent material, an inert filler, and a "glue" that keeping the parts together as a whole plug.

The product inserted into the tear duct immediately contacts eye fluids, resulting in a slow and precise diffusion release of the drug, which lowers the intraocular pressure.

The Technology

The smart medical device is based on a unique concept: using the tear duct as a point of entry for a device that releases medication to the eye. The tear duct is currently used to insert an inert simple, commercial silicone plug, which functions as a cap designed to reduce tear drainage and improve the condition of dry eye patients.

Eximore has developed a unique, first-of-its-kind "smart" plug based on a composite of advanced materials inserted into the tear duct to treat eye diseases.

The technology was first conceptualized by Prof. Guy Ben Simon from Tel Hashomer Hospital - to incorporate a generic drug already approved for use in the market, with a recognized safety profile, within a device inserted into the tear duct. Since then, Eximore has been developing this idea, to bring it to the market.

The smart plug needs to be replaced every 3-6 months as part of these patient's regular doctor appointments. The insertion of the device is done in the doctor's clinic, in a simple procedure, without pain or any need for anesthesia or surgery. It contains enough medicine for up to a year of treatment. This way, both the doctor and patient can be assured that the disease is being treated according to protocol while preventing possible deterioration.

Eximore's technology signals a new age of innovation. In addition to the benefits of a minimized device containing enough medication for long-term treatment, the technology offers another important advantage: combining several different drugs at once. Patients can receive multiple meds from the same device, meeting a need relevant to an even greater market and producing a platform with great potential for further additional uses.


Clinical Trials

After proving its efficacy and safety in pre-clinical trials, Eximore is in the final stages of a clinical trial (phase I) in humans, as part of research collaborations with international hospitals, for two of its developed products.

Effective pressure reduction in pre-clinical trials:

The results of the trials have shown, so far, that in glaucoma conditions, the plug effectively releases the required drug, lowers intraocular pressure more efficiently and safely than eye drops, and allows for continuous treatment for over three months.

Results of a 3-month treatment to reduce pressure in humans with a plug containing drug E (orange), compared to standard therapy with eye drops (blue) - the concluding graph shows that the device lowers the pressure effectively:

In dry eye conditions, another development the company intends to complete and launch after its first glaucoma product, initial clinical trials in humans have shown that the product significantly improves patient condition, successfully treats inflammation, and more effectively restores tear functions when compared to eye drop treatment.




Eyal Sheetrit
Founder and CEO
Eyal Sheetrit is an entrepreneur with extensive experience in product development in the medical and biotech fields. He acquired vast experience as an innovation manager at Ethicon Biosurgery (J&J) and as a strategic consultant. He holds a BSc and ME in biotechnological and biomedical engineering from the Technion and an MBA from the Faculty of Business Administration at Tel Aviv University. He co-founded the company in 2013.

  • Founder
Dr. Guy Tomer
VP of Development
Dr. Guy Tomer holds a doctorate in biochemistry and is a licensed pharmacist certified by the Ministry of Health. He has 16 years of experience leading the development of medical devices combined with biological materials and drugs, including the concept phase, formulation, production, and analytical methods. His recent positions included Chief Scientist of the Lifebond Company and Director of Technologies at Seevix Material Sciences.

Dr. Yaniv Barkana
Medical Director
Dr. Yaniv Barkana is an expert in ophthalmology, cataract, and glaucoma surgery and is director of the Glaucoma Research and Innovation Laboratory at Sheba Tel Hashomer Medical Center. He has conducted many studies in ophthalmology, which he presented in lectures at international conferences, and has been published in leading professional journals. Until December 2015, he served as a senior ophthalmologist and surgeon in the ophthalmology department at Assaf Harofeh Medical Center and as a senior lecturer at the Tel Aviv University School of Medicine. Subsequently, he initiated and managed the tele-glaucoma service at Poria Hospital until September 2020. Dr. Barkana served as chairman of the Glaucoma Department of the Israel Medical Association for four years.

Dr. Tal Lavi
Director of Clinical Research
With extensive experience in the clinical field, Dr. Tal Lavi serves as Eximore‘s clinical research director. Previous positions include Senior Clinical Trials Manager at GSAP; Clinical Trial Manager at Check-Cap Ltd and BrainsGate Ltd; and CRA Senior Manager at Orsan Medical Technologies Ltd. Dr. Lavi has a Ph.D. and is a Postdoctoral Fellow in Molecular Cancer, Programmed Cell Apoptosis.

Prof. Guy Ben Simon
Founder, oculoplastics expert, and opinion leader
Prof. Guy Ben Simon is an ophthalmologist who specializes in oculoplastics, specifically in eyelid surgery, eye sockets, and tear ducts. He serves as the Institute of Plastic Surgery director for eye sockets at Sheba Tel Hashomer Medical Center. He owns a private clinic at Medica Medical Center in Tel Aviv. His degree in medicine is from the Hebrew University, Jerusalem (1987-1993), with a specialization in ophthalmology at the Goldschlager Ophthalmic Institute, Sheba Medical Center, Tel Hashomer (1999-2003). Advanced training includes continued studies in ophthalmology at the S. Sackler School of Medicine, Tel Aviv University (1986-1987), specializing in the eye socket, eyelid, and tear duct surgery; Jules Stein Eye Institute, UCLA, LA, CA, USA (2003-2004); and a specialization in the eye socket, eyelid and tear duct surgery - Royal Victorian Eye and Ear Hospital, Melbourne, Australia (2005).

  • Founder

Financial data

Financial data



Currently there are no updates in this pitch

The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968.
Under this model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors, who are not qualified investors, and the round of financing is not in the format of an offering arrangement ("רכז הצעה"), as defined in the Securities Law.
Follow us